Nakajima Hiroo, Mizuta Naruhiko, Sakaguchi Koichi, Fujiwara Ikuya, Mizuta Mitsuhiko, Furukawa Chiharu, Chang Young-Chae, Magae Junji
Department of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine, Kamikyo-ku, Kyoto, Japan.
J Antibiot (Tokyo). 2007 Nov;60(11):682-9. doi: 10.1038/ja.2007.87.
Estrogen receptor-negative breast cancers generally are highly malignant, resistant to chemotherapy and poorly prognostic. Here we demonstrate that estrogen receptor-negative human breast cancer cell lines highly express Fra-1, c-Fos and c-Jun, components of the transcription factor, activator protein-1 (AP-1). Retrospective observation of breast cancer tissues obtained by core needle biopsy before surgery from stages II and III patients demonstrates that Fra-1 expression is high in estrogen receptor-negative human breast cancers, and negatively correlated to paclitaxel sensitivity. Ascochlorin, which suppresses cellular AP-1 activity, selectively kills estrogen receptor-negative human and mouse breast cancer cell lines, and prolongs the survival time of mice implanted with an estrogen receptor-negative mammary carcinoma. These results suggest that chemotherapy targeting AP-1 activity is a potent strategy for estrogen receptor-negative human breast cancers.
雌激素受体阴性乳腺癌通常具有高度恶性,对化疗耐药且预后较差。在此我们证明,雌激素受体阴性的人乳腺癌细胞系高表达转录因子激活蛋白-1(AP-1)的组成成分Fra-1、c-Fos和c-Jun。对II期和III期患者术前通过粗针活检获得的乳腺癌组织进行回顾性观察表明,Fra-1在雌激素受体阴性的人乳腺癌中高表达,且与紫杉醇敏感性呈负相关。抑制细胞AP-1活性的灰黄霉素选择性杀死雌激素受体阴性的人及小鼠乳腺癌细胞系,并延长接种雌激素受体阴性乳腺癌的小鼠的存活时间。这些结果表明,针对AP-1活性的化疗是治疗雌激素受体阴性人乳腺癌的有效策略。